At a glance
Effects
- Blood glucose control: Rapidly lowers circulating blood glucose by driving uptake into skeletal muscle, liver and adipose tissue [1][2].
- Anabolic / nutrient partitioning: Promotes glycogen synthesis in muscle and liver, and enhances amino acid uptake, supporting muscle protein synthesis [1].
- Suppression of hepatic glucose output: Inhibits glycogenolysis and gluconeogenesis in the liver, reducing fasting glucose levels [2][6].
- Lipid metabolism: Inhibits lipolysis and promotes fatty acid esterification, lowering free fatty acid and triglyceride concentrations [3].
- Potassium shift: Drives potassium from the extracellular to intracellular space, which is used therapeutically in hyperkalaemia but can become a hazard [4][5].
Peptide hormone / antidiabetic agent
~1.5 h (regular insulin, subcutaneous)
Subcutaneous injection (primary); IV in clinical settings
~30 min after subcutaneous administration
Narrow — blood glucose monitoring mandatory
About Insulin
Every point here is drawn from public medical and harm-reduction sources. A bracketed number after a claim — like [1]— is a reference: tap it to open the exact source it's based on (numbered list at the bottom). It is not a rating or score. Educational information, not medical advice.
Product specifics
- Est. delivery
- 3–7 business days · EU tracked
Product details as stated by the vendor (claims, not independently verified). Delivery is our standard EU estimate.
What it is
Insulin is a peptide hormone classified as an antidiabetic agent and hormone replacement that is essential for regulating blood glucose [1]. It is produced naturally by pancreatic beta cells and, when administered exogenously, is used to manage both type 1 and type 2 diabetes mellitus, as well as being misused in athletic contexts for its potent anabolic and nutrient-partitioning properties [1][2].
How it works
Insulin binds to specific insulin receptors on cell surfaces, activating receptor tyrosine kinase activity and initiating intracellular signalling cascades [2]. This drives translocation of GLUT4 glucose transporters to the cell membrane, allowing glucose uptake into muscle and fat cells [2]. Simultaneously, insulin suppresses hepatic glucose production and promotes glycogen and protein synthesis, making it a powerful anabolic signal that positively regulates cellular growth and energy storage [1].
Risks & side effects
Most important: Hypoglycaemia (dangerously low blood glucose) is by far the most common and life-threatening adverse effect of insulin; depending on severity it can cause confusion, seizures, coma and death [7][8]. Even a modest miscalculation of dose, missed meal, or unexpected exercise can precipitate a severe episode in a non-diabetic user, where the usual counter-regulatory glucagon response may be insufficient [8].
Common
Serious
- Severe hypoglycaemia: loss of consciousness, seizures, coma, death [8][7]
- Hypokalemia: insulin shifts potassium intracellularly, risking cardiac arrhythmias, muscle weakness, respiratory compromise [4][5]
- Hypoglycaemia-induced arrhythmia or cardiovascular event [5]
- Insulin overdose toxicity: hypotension, arrhythmias, coma [4]
- Development of insulin antibodies and insulin resistance with long-term use [4]
Safety & harm reduction
- Active hypoglycaemia — insulin is absolutely contraindicated when blood glucose is already low [9]
- Insulinoma (tumour causing excess endogenous insulin) — exogenous insulin greatly worsens hypoglycaemia risk [4]
- Uncorrected hypokalaemia — insulin drives potassium further intracellularly and can precipitate fatal arrhythmia [4][5]
- Known cresol sensitivity — most insulin preparations contain cresol as a preservative [7]
- Frequent blood glucose monitoring (pre-meal, post-meal, bedtime, and during any unusual activity) [4][7]
- Serum potassium monitoring, especially in patients on diuretics or other potassium-lowering agents [5][7]
- Regular HbA1c measurement to assess glycaemic control over time [3]
- Monitor renal and hepatic function — impairment slows insulin clearance and increases hypoglycaemia risk [9]
- Diuretics (e.g. thiazides, loop): additive hypokalaemia risk [7]
- Thiazolidinediones (TZDs, e.g. pioglitazone): can cause fluid retention and worsen heart failure when combined with insulin [9]
- Other glucose-lowering agents (sulphonylureas, GLP-1 agonists): additive hypoglycaemia risk [8]
- Beta-blockers: can mask tachycardia warning signs of hypoglycaemia and prolong hypoglycaemic episodes [9]
- Alcohol: potentiates hypoglycaemic effect of insulin [9]
- Corticosteroids, sympathomimetics: antagonise insulin, raising blood glucose and increasing insulin requirements [9]
- Always have fast-acting carbohydrates (glucose gel, dextrose tablets, juice) immediately available when using insulin [8]
- Carry a glucagon emergency kit; ensure someone nearby knows how to administer it [8]
- Rotate injection sites to prevent lipodystrophy; inspect sites regularly [4]
- Never skip or significantly delay a meal after insulin administration [8]
- Correct any hypokalaemia before administering insulin [4][5]
- In non-diabetic (performance) use, extreme caution is warranted — even small errors can cause fatal hypoglycaemia; this use is outside any medical guidance
Dosage context
Insulin dosing is highly individualised and must be prescribed and titrated by a qualified clinician based on body weight, blood glucose levels, diet, activity, and formulation type [7]. For regular human insulin given subcutaneously, clinical prescribing information reflects typical starting doses in the range of 0.5–1 unit/kg/day for type 1 diabetes, split across meals and basal needs — but this is illustrative context only, not a target [7][9]. No safe non-medical dose exists; any use outside medical supervision is dangerous. Sources note that insulin has a narrow therapeutic index and that blood glucose must be monitored continuously [7].
Sources
- 1.StatPearls – Insulin (NCBI Bookshelf)
- 2.StatPearls – Human Insulin (NCBI Bookshelf)
- 3.PMC – Mechanism of Action of Inhaled Insulin (Mehta et al., 2019)
- 4.FDA Prescribing Information – HUMULIN N (Eli Lilly)
- 5.FDA Prescribing Information – HUMALOG (insulin lispro)
- 6.Nature – Mechanism of Action of Insulin (Dunn et al.)
- 7.PubMed – Exploring mechanisms of insulin action (2024)
- 8.MedlinePlus – Hypoglycemia
- 9.Mayo Clinic – Insulin human regular (subcutaneous route)
- 10.USPTO / Patent doc – Regular Insulin pharmacokinetics (half-life, onset)
This information is provided for educational and harm-reduction purposes only. It is not medical advice. These substances can carry serious health risks; effects and safe use vary by individual. Consult a qualified healthcare professional before use. Legal status varies by country — it is your responsibility to know your local law. We do not encourage misuse.
Other options for Insulin· 8 offers
Same compound from different labs/brands and pack sizes. Tap a row to switch brand — the price and buy button update instantly.
This compound comes in different forms (e.g. injectable vs oral vs topical). Cost per mg is only comparable within the same form.
| Brand | Form | Strength | Pack | Price | Per mg |
|---|---|---|---|---|---|
Generic | — | — | 54,90 € | — | |
Generic | vial | 100 iu/ml | 10 ml | 94,90 € | — |
GenericSelected | pen | 100 iu/ml | 5 pen | 109,99 € | — |
Eli Lilly | pen | 100 iu/ml | 5 pen | 109,99 € | — |
Sanofi | — | — | 3×3 ml | 369,99 € | — |
Generic | pen | 100 iu/ml | 5×3 ml | 389,99 € | — |
Generic | pen | 100 iu/ml | 5×3 ml | 389,99 € | — |
Sanofi | pen | 100 iu/ml | 10 pen | 489,99 € | — |